Master’s Supervisor at Hebei Medical University , China
Dr. Hao Han is an accomplished pharmaceutical scientist and dedicated lecturer at the Institute of Pharmaceutical Sciences, Hebei Medical University. Throughout his academic and professional journey, Dr. Han has consistently demonstrated a commitment to advancing pharmaceutical sciences, particularly in the realms of supramolecular drug delivery systems and pharmaceutical cocrystals. His research contributions stand out for their depth and innovative approach, particularly in optimizing drug combinations for enhanced therapeutic effects. As a scholar, Dr. Han has distinguished himself by combining a meticulous scientific approach with a vision for real-world pharmaceutical applications, enriching the fields of drug formulation and delivery.
profile
scopus
Education
Dr. Han’s educational background reflects a strong foundation in both pharmacy and biopharmaceuticals. He completed his Ph.D. in Pharmaceutics at Hebei Medical University’s School of Pharmaceutical Sciences in July 2023, following a Master of Science in Pharmacy from the same institution in 2020. Earlier, he earned his Bachelor of Engineering degree in Biopharmaceuticals from Fujian Medical University in 2016. This solid academic training has not only given him technical knowledge but also equipped him with the critical thinking and problem-solving skills necessary to tackle complex pharmaceutical research questions.
Experience
Dr. Han’s research experience is both rich and diverse. Currently serving as a Postdoctoral Researcher at Hebei Medical University since October 2023, his focus lies in the burgeoning field of supramolecular pharmaceuticals. Prior to his postdoctoral appointment, he was deeply engaged in pharmaceutical research throughout his doctoral and master’s studies, contributing substantially to understanding the synergistic mechanisms of drug combinations, preclinical evaluations, and the development of pharmaceutical cocrystals. His scientific work elegantly bridges theory with application, often aiming to improve drug efficacy and reduce side effects through novel formulation strategies.
Research Interest
Dr. Han’s research interests are deeply rooted in the rational design of supramolecular drug delivery systems, preclinical evaluation of pharmaceutical cocrystals, and synergistic drug action mechanisms. His primary scientific focus revolves around enhancing drug bioavailability and therapeutic performance through innovative molecular designs and formulation strategies. By dissecting the interaction mechanisms between co-crystal components and exploring their synergistic effects, Dr. Han aims to create efficient, safer, and more targeted therapeutic agents, offering new solutions for complex diseases, particularly cancer.
Award
Dr. Han’s exceptional research contributions have earned him recognition in both academic and professional circles. His works have been highly cited, a testament to the relevance and influence of his scientific findings in the global pharmaceutical community. While his awards and nominations are still accumulating as he progresses in his academic career, the strength of his publications and collaborations underscores his reputation as a promising leader in pharmaceutical sciences.
Publication
Dr. Hao Han has made substantial contributions to the field of pharmaceutical sciences, with a focus on supramolecular drug delivery systems and pharmaceutical cocrystals, reflected in his published research in internationally recognized journals.
Han Hao, Xinming Jia, Tiantian Ren, Yingfeng Du, Jing Wang. “Novel insight into the mechanism underlying synergistic cytotoxicity from two components in 5-Fluorouracil-phenylalanine co-crystal based on cell metabolomics.” European Journal of Pharmaceutics and Biopharmaceutics, 2022, 180, 181–189. This publication has been cited by several follow-up studies, reflecting its significance in the development of synergistic cytotoxic drug designs.
Han Hao, Tiantian Ren, Cuilu Quan, Jing Wang. “Chiral 5-fluorouracil-arginine cocrystals screened by wet powder grinding method: Leading to synergistic anti-tumor and alleviate cardiotoxicity.” Powder Technology, 2024, 436, 119487. This paper has been cited for its innovative approach to enhancing anticancer drug effects while reducing side effects.
Han Hao, Yao Zhang, Xiaoxiao Hu, Wei Guo, Caiqin Yang, Jing Wang. “Cocrystallization of 5-fluorouracil with gallic acid: A novel 5-fluorouracil cocrystal displaying synergistic anti-tumor activity both in oral and intraperitoneal injection administration.” European Journal of Pharmaceutics and Biopharmaceutics, 2023, 187, 12-23. Widely referenced for its clinical application potential in oncology.
Xin-ming Jia, Han Hao, Qian Zhang, Meng-xin Yang, Nan Wang, Shi-lin Sun, Ze-nan Yang, Yi-ran Jin, Jing Wang, Ying-feng Du. “The bioavailability enhancement and insight into the action mechanism of poorly soluble natural compounds from co-crystals preparation: Oridonin as an example.” Phytomedicine, 2024, 122, 155179. This paper has been cited by researchers interested in enhancing the bioavailability of natural products.
Lina Zhang, Yutao Jia, Han Hao, Mi Wang, Jing Wang. “Mitochondria-targeted liposome-enveloped covalent organic framework co-delivery system for enhanced tumor therapy.” Microporous and Mesoporous Materials, 2022, 344, 112198. This innovative nanotechnology research has been cited for its promising therapeutic applications.
Zhichuan Xin, Yanting Shen, Han Hao, Lina Zhang, Xiaoxiao Hu, Jing Wang. “Hyaluronic acid coated mesoporous carbon-copper peroxide for H2O2 self-supplying and near-infrared responsive multi-mode breast cancer oncotherapy.” Colloids and Surfaces B: Biointerfaces, 2022, 218, 112776. Frequently cited in the field of multifunctional drug delivery systems for cancer treatment.
Mi Wang, Lina Zhang, Han Hao, Xiaoxiao Hu, Zhichuan Xin, Yanyan Zhu, Yanting Shen, Jing Wang. “Synergistic H2O2 self-supplying and NIR-responsive drug delivery nanoplatform for chemodynamic-photothermal-chemotherapy.” Colloids and Surfaces B: Biointerfaces, 2022, 213, 112412. This work has gained citations for its creative integration of photothermal and chemodynamic therapy concepts.
Conclusion
Dr. Hao Han exemplifies the qualities of an outstanding researcher through his dedication, innovation, and scholarly excellence. His contributions are not only valuable to the scientific community but also hold promising implications for patient care and therapeutic advancement. Given his research achievements, depth of knowledge, and consistent publication in respected journals, Dr. Han is a highly deserving candidate for the Best Researcher Award.